

Global Bladder Cancer Treatment Market Report and Forecast 2023-2031

Market Report | 2023-03-15 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Bladder Cancer Treatment Market Report and Forecast 2023-2031

Global Bladder Cancer Treatment Market Outlook

The global bladder cancer treatment market size was valued at USD 4.3 billion in 2022 and is projected to grow at a CAGR of 9.31% during the forecast period of 2023-2031, reaching a value of USD 8.98 billion by 2031. The market growth can be attributed to the increasing prevalence of bladder cancer and the rising awareness about cancer treatment.

Global Bladder Cancer Treatment Market: Introduction

Bladder cancer treatment involves medical interventions aimed at treating cancer that develops in the bladder, usually originating in the urothelial cells lining the inside of the bladder. The treatment options include surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. The increasing prevalence of bladder cancer, coupled with advancements in diagnostic techniques, is driving the demand for effective bladder cancer treatments. Factors such as aging populations, increased tobacco use, and exposure to harmful chemicals are expected to contribute to market growth.

Technological advancements and new treatment options are also driving the growth of the bladder cancer treatment market. Improved diagnostic techniques, such as advanced imaging and molecular testing, have led to earlier detection and more targeted treatment plans. Additionally, advancements in immunotherapy and targeted therapy have improved patient outcomes and expanded treatment options.

Bladder Cancer Epidemiology

According to the World Health Organization, bladder cancer is the 10th most common cancer globally, with approximately 573,000 new cases and 213,000 deaths in 2020. The prevalence of bladder cancer is higher in men than women and tends to increase with age. The majority of bladder cancer cases are diagnosed in individuals aged 65 and older. Risk factors for developing bladder cancer include smoking, exposure to certain chemicals and substances, chronic bladder inflammation, and a family history of the disease.

Bladder Cancer Treatment Market Segmentations

The market can be segmented based on type, diagnosis methods, treatment methods, treatment channel, and major regions:

Market Breakup by Type

-□ Invasive Bladder Cancer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- o Non-Muscle-Invasive Bladder Cancer
- o Muscle-Invasive Bladder Cancer
- Transitional Bladder Cancer
- Squamous Cell Bladder Cancer
- Others

Market Breakup by Diagnosis Methods

- Cystoscopy
- Biopsy
- Urine Cytology
- Imaging Tests

Market Breakup by Treatment Method

- Surgery
- Chemotherapy
- Radiation Therapy
- Immunotherapy
- Targeted Therapy
- Others

Market Breakup by End-User

- Public
- Private

Market Breakup by Region

- North America
- ? United States of America
- ? Canada
- Europe
- ? United Kingdom
- ? Germany
- ? France
- ? Italy
- ? Others
- Asia Pacific
- ? China
- ? Japan
- ? India
- ? ASEAN
- ? Australia
- ? Others
- Latin America
- ? Brazil
- ? Argentina
- ? Mexico
- ? Others
- Middle East and Africa
- ? Saudi Arabia
- ? United Arab Emirates
- ? Nigeria
- ? South Africa

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Bladder Cancer Treatment Market Analysis

North America currently dominates the global bladder cancer treatment market, driven by factors such as a higher prevalence of bladder cancer, well-established healthcare infrastructure, increased funding for research and development, and early adoption of advanced treatment options. Europe also holds a significant share of the global market, with countries such as the UK, Germany, and France leading the way. The growth of the European market can be attributed to an aging population, increased healthcare spending, and advancements in diagnostic and treatment technologies. The Asia Pacific region is expected to experience significant growth in the bladder cancer treatment market in the coming years, driven by factors such as a large population base, increasing awareness about cancer and its treatment, and growing investments in healthcare infrastructure. In addition, government initiatives to improve cancer care and the expanding presence of major market players in the region are contributing to the growth of the market in Asia Pacific.

Latin America and the Middle East and Africa regions are also expected to witness growth in the bladder cancer treatment market, driven by factors such as increasing government initiatives for cancer control and prevention, and the development of healthcare infrastructure. However, limited access to advanced treatment options and the high cost of cancer care in these regions may pose challenges to market growth.

Key Players in the Global Bladder Cancer Treatment Market

The report provides a detailed analysis of the key players involved in the bladder cancer treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:

- AstraZeneca Plc.
- Bristol-Myers Squibb Co.
- Celgene Corporation
- Pfizer Inc.
- GlaxoSmithKline Plc.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Novartis International AG
- Sanofi S.A.
- Merck & Co. Inc.
- Genentech Inc.
- Johnson & Johnson Services, Inc
- Viventia Bio Inc.
- Spectrum Pharmaceuticals, Inc.
- Herantis Pharma Plc.
- Taris Biomedical LLC
- Prometic Life Sciences Inc.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.1.1 Research Objectives
 - 1.1.2 Key Findings of the Report
 - 1.2 Limitations of the Study and Scope for Future Research
- 2 Research Methodology
- 3 Executive Summary
- 4 Global Bladder Cancer Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.1 Guidelines and Stages
- 4.2 Pathophysiology
- 4.3 Screening and Diagnosis
- 4.4 Treatment Pathway
- 5 Patient Profile
 - 5.1 Patient Profile Overview
 - 5.2 Patient Psychology and Emotional Impact Factors
 - 5.3 Risk Assessment and Treatment Success Rate
- 6 Global Bladder Cancer Treatment Market
 - 6.1 Global Bladder Cancer Treatment Market Overview
 - 6.2 Global Bladder Cancer Treatment Market Analysis
 - 6.2.1 Market Overview
 - 6.2.1.1 Global Bladder Cancer Treatment Market Historical Value (2016-2022)
 - 6.2.1.2 Global Bladder Cancer Treatment Market Forecast Value (2023-2031)
 - 6.2.2 Global Bladder Cancer Treatment Market by Type
 - 6.2.2.1 Market Overview
 - 6.2.2.1.1 Invasive Bladder Cancer
 - 6.2.2.1.1.1 Non-Muscle-Invasive Bladder Cancer
 - 6.2.2.1.1.2 Muscle-Invasive Bladder Cancer
 - 6.2.2.1.2 Transitional Bladder Cancer
 - 6.2.2.1.3 Squamous Cell Bladder Cancer
 - 6.2.2.1.4 Others
 - 6.2.3 Global Bladder Cancer Treatment Market by Diagnosis Method
 - 6.2.3.1 Market Overview
 - 6.2.3.1.1 Cystoscopy
 - 6.2.3.1.2 Biopsy
 - 6.2.3.1.3 Urine Cytology
 - 6.2.3.1.4 Imaging Tests
 - 6.2.4 Global Bladder Cancer Treatment Market by Treatment Method
 - 6.2.4.1 Market Overview
 - 6.2.4.1.1 Surgery
 - 6.2.4.1.2 Intravesical Chemotherapy
 - 6.2.4.1.3 Systemic Chemotherapy
 - 6.2.4.1.4 Radiation Therapy
 - 6.2.4.1.5 Immunotherapy
 - 6.2.4.1.6 Targeted Therapy
 - 6.2.5 Global Bladder Cancer Treatment Market by Treatment Channel
 - 6.2.5.1 Market Overview
 - 6.2.5.1.1 Public
 - 6.2.5.1.2 Private
 - 6.2.6 Global Bladder Cancer Treatment Market by Region
 - 6.2.6.1 Market Overview
 - 6.2.6.1.1 North America
 - 6.2.6.1.2 Europe
 - 6.2.6.1.3 Asia Pacific
 - 6.2.6.1.4 Latin America
 - 6.2.6.1.5 Middle East and Africa

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.2.6.2 North America
 - 6.2.6.2.1 Historical Trend (2016-2022)
 - 6.2.6.2.2 Forecast Trend (2023-2031)
 - 6.2.6.2.3 Break Up by Country
 - 6.2.6.2.3.1 United States of America
 - 6.2.6.2.3.2 Canada
- 6.2.6.3 Europe
 - 6.2.6.3.1 Historical Trend (2016-2022)
 - 6.2.6.3.2 Forecast Trend (2023-2031)
 - 6.2.6.3.3 Break Up by Country
 - 6.2.6.3.3.1 United Kingdom
 - 6.2.6.3.3.2 Germany
 - 6.2.6.3.3.3 France
 - 6.2.6.3.3.4 Italy
 - 6.2.6.3.3.5 Others
- 6.2.6.4 Asia Pacific
 - 6.2.6.4.1 Historical Trend (2016-2022)
 - 6.2.6.4.2 Forecast Trend (2023-2031)
 - 6.2.6.4.3 Break Up by Country
 - 6.2.6.4.3.1 China
 - 6.2.6.4.3.2 Japan
 - 6.2.6.4.3.3 India
 - 6.2.6.4.3.4 ASEAN
 - 6.2.6.4.3.5 Australia
 - 6.2.6.4.3.6 Others
- 6.2.6.5 Latin America
 - 6.2.6.5.1 Historical Trend (2016-2022)
 - 6.2.6.5.2 Forecast Trend (2023-2031)
 - 6.2.6.5.3 Break Up by Country
 - 6.2.6.5.3.1 Brazil
 - 6.2.6.5.3.2 Argentina
 - 6.2.6.5.3.3 Mexico
 - 6.2.6.5.3.4 Others
- 6.2.6.6 Middle East and Africa
 - 6.2.6.6.1 Historical Trend (2016-2022)
 - 6.2.6.6.2 Forecast Trend (2023-2031)
 - 6.2.6.6.3 Break Up by Country
 - 6.2.6.6.3.1 Saudi Arabia
 - 6.2.6.6.3.2 United Arab Emirates
 - 6.2.6.6.3.3 Nigeria
 - 6.2.6.6.3.4 South Africa
 - 6.2.6.6.3.5 Others

7 Current Scenario Evaluation and Regulatory Framework

7.1 Emerging Therapies and Clinical Trials Synopsis

7.2 Patent Landscape

7.2.1 Patent Overview

7.2.1.1 Patent Status and Expiry

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2.1.2 Timelines from Drug Development to Commercial Launch
 - 7.2.1.3 New Drug Application
 - 7.2.1.3.1 Documentation and Approval Process
 - 7.3 Cost of Treatment
 - 7.4 Regulatory Framework
 - 7.4.1 Regulatory Overview
 - 7.4.1.1 US FDA
 - 7.4.1.2 EU EMA
 - 7.4.1.3 INDIA CDSCO
 - 7.4.1.4 JAPAN PMDA
 - 7.4.1.5 Others
- 8 Challenges and Unmet Needs
 - 8.1 Treatment Pathway Challenges
 - 8.2 Compliance and Drop-Out Analysis
 - 8.3 Awareness and Prevention Gaps
- 9 Global Bladder Cancer Treatment Market Dynamics
 - 9.1 Market Drivers and Constraints
 - 9.2 SWOT Analysis
 - 9.3 Porter's Five Forces Model
 - 9.4 Key Demand Indicators
 - 9.5 Key Price Indicators
 - 9.6 Industry Events, Initiatives and Trends
 - 9.7 Value Chain Analysis
- 10 Supplier Landscape
 - 10.1 AstraZeneca Plc.
 - 10.1.1 Company Overview
 - 10.1.2 Product Portfolio
 - 10.1.3 Demographic Reach and Achievements
 - 10.1.4 Mergers and Acquisitions
 - 10.1.5 Certifications
 - 10.2 Bristol-Myers Squibb Co.
 - 10.2.1 Company Overview
 - 10.2.2 Product Portfolio
 - 10.2.3 Demographic Reach and Achievements
 - 10.2.4 Mergers and Acquisitions
 - 10.2.5 Certifications
 - 10.3 Celgene Corporation
 - 10.3.1 Company Overview
 - 10.3.2 Product Portfolio
 - 10.3.3 Demographic Reach and Achievements
 - 10.3.4 Mergers and Acquisitions
 - 10.3.5 Certifications
 - 10.4 Pfizer Inc.
 - 10.4.1 Company Overview
 - 10.4.2 Product Portfolio
 - 10.4.3 Demographic Reach and Achievements
 - 10.4.4 Mergers and Acquisitions

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.4.5 Certifications
- 10.5 GlaxoSmithKline Plc.
 - 10.5.1 Company Overview
 - 10.5.2 Product Portfolio
 - 10.5.3 Demographic Reach and Achievements
 - 10.5.4 Mergers and Acquisitions
 - 10.5.5 Certifications
- 10.6 Eli Lilly and Company
 - 10.6.1 Company Overview
 - 10.6.2 Product Portfolio
 - 10.6.3 Demographic Reach and Achievements
 - 10.6.4 Mergers and Acquisitions
 - 10.6.5 Certifications
- 10.7 F. Hoffmann-La Roche AG
 - 10.7.1 Company Overview
 - 10.7.2 Product Portfolio
 - 10.7.3 Demographic Reach and Achievements
 - 10.7.4 Mergers and Acquisitions
 - 10.7.5 Certifications
- 10.8 Novartis International AG
 - 10.8.1 Company Overview
 - 10.8.2 Product Portfolio
 - 10.8.3 Demographic Reach and Achievements
 - 10.8.4 Mergers and Acquisitions
 - 10.8.5 Certifications
- 10.9 Sanofi S.A.
 - 10.9.1 Company Overview
 - 10.9.2 Product Portfolio
 - 10.9.3 Demographic Reach and Achievements
 - 10.9.4 Mergers and Acquisitions
 - 10.9.5 Certifications
- 10.10 Merck & Co. Inc.
 - 10.10.1 Company Overview
 - 10.10.2 Product Portfolio
 - 10.10.3 Demographic Reach and Achievements
 - 10.10.4 Mergers and Acquisitions
 - 10.10.5 Certifications
- 10.11 Genetech Inc.
 - 10.11.1 Company Overview
 - 10.11.2 Product Portfolio
 - 10.11.3 Demographic Reach and Achievements
 - 10.11.4 Mergers and Acquisitions
 - 10.11.5 Certifications
- 10.12 Johnson & Johnson Services, Inc
 - 10.12.1 Company Overview
 - 10.12.2 Product Portfolio
 - 10.12.3 Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.12.4 Mergers and Acquisitions
- 10.12.5 Certifications
- 10.13 Viventia Bio Inc.
 - 10.13.1 Company Overview
 - 10.13.2 Product Portfolio
 - 10.13.3 Demographic Reach and Achievements
 - 10.13.4 Mergers and Acquisitions
 - 10.13.5 Certifications
- 10.14 Spectrum Pharmaceuticals, Inc.
 - 10.14.1 Company Overview
 - 10.14.2 Product Portfolio
 - 10.14.3 Demographic Reach and Achievements
 - 10.14.4 Mergers and Acquisitions
 - 10.14.5 Certifications
- 10.15 Herantis Pharma Plc.
 - 10.15.1 Company Overview
 - 10.15.2 Product Portfolio
 - 10.15.3 Demographic Reach and Achievements
 - 10.15.4 Mergers and Acquisitions
 - 10.15.5 Certifications
- 10.16 Taris Biomedical LLC
 - 10.16.1 Company Overview
 - 10.16.2 Product Portfolio
 - 10.16.3 Demographic Reach and Achievements
 - 10.16.4 Mergers and Acquisitions
 - 10.16.5 Certifications
- 10.17 Prometic Life Sciences Inc.
 - 10.17.1 Company Overview
 - 10.17.2 Product Portfolio
 - 10.17.3 Demographic Reach and Achievements
 - 10.17.4 Mergers and Acquisitions
 - 10.17.5 Certifications
- 11 Recommendations and Discussion
- 12 Global Bladder Cancer Treatment Drugs Distribution Model (Additional Insight)
 - 12.1 Overview
 - 12.2 Potential Distributors
 - 12.3 Key Parameters for Distribution Partner Assessment
- 13 Payment Methods (Additional Insight)
 - 13.1 Government Funded
 - 13.2 Private Insurance
 - 13.3 Out-of-Pocket

Global Bladder Cancer Treatment Market Report and Forecast 2023-2031

Market Report | 2023-03-15 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com